摘要
目的评估经皮导入复方甘草酸苷注射液辅助治疗红斑毛细血管扩张型玫瑰痤疮的疗效和安全性。方法本研究为随机对照试验,前瞻性纳入2024年3至10月四川省人民医院初次诊断为红斑毛细血管扩张型玫瑰痤疮患者60例,按照随机数字表法分为观察组和对照组,每组30例。观察组包括男6例,女24例,年龄18~60(38.9±9.8)岁;对照组包括男4例,女26例,年龄18~60(35.7±10.1)岁。观察组接受中频药物导入治疗仪经皮导入复方甘草酸苷注射液联合口服阿奇霉素、硫酸羟氯喹治疗;对照组接受口服阿奇霉素、硫酸羟氯喹治疗。分别于治疗前及治疗后2、4、6、8周进行疗效评价,观察指标包括红斑面积百分比、角质层含水量、经皮水分丢失(TEWL)、临床医师红斑评估(CEA)量表、红斑及毛细血管扩张评分、皮肤病生活质量指数(DLQI)、有效率。同时记录两组患者治疗过程中的不良反应。结果两组患者治疗后各时间点与同组治疗前比较,红斑面积百分比、TEWL、CEA量表评分、红斑及毛细血管扩张评分、DLQI均降低,角质层含水量均升高(均P<0.05)。治疗2、4、6、8周后,观察组的红斑面积百分比、红斑及毛细血管扩张评分均低于对照组,角质层含水量均高于对照组(均P<0.05)。治疗4、6、8周后,观察组的TEWL、CEA量表评分、DLQI均低于对照组(均P<0.05)。治疗4周后,观察组有效率为56.7%(17/30),高于对照组的23.3%(7/30,P=0.046);治疗6周后,观察组有效率为83.3%(25/30),高于对照组的50.0%(15/30,P=0.020);治疗8周后,观察组有效率为86.7%(26/30),高于对照组的66.7%(20/30,P<0.001)。两组患者治疗后均无严重不良反应。结论经皮导入复方甘草酸苷注射液辅助治疗红斑毛细血管扩张型玫瑰痤疮疗效较好,安全性高。
Objective To evaluate the efficacy and safety of transdermal delivery of compound glycyrrhizin injection as an adjunctive treatment for erythematotelangiectatic rosacea(ETR).Methods This was a randomized controlled trial conducted from March to October 2024.At Sichuan Provincial People′s Hospital,60 patients with newly diagnosed ETR were prospectively enrolled and randomized by a random number table into study group[n=30;6 male and 24 female;aged 18-60(38.9±9.8)years]and control group[n=30;4 male and 26 female;aged 18-60(35.7±10.1)years].The study group received transdermal delivery of compound glycyrrhizin injection by a medium-frequency drug-delivery therapeutic apparatus together with oral azithromycin and hydroxychloroquine sulfate,whereas the control group received oral azithromycin and hydroxychloroquine sulfate.The efficacy evaluations were conducted at baseline and at weeks 2,4,6,and 8 post-treatment.Outcome measures included percentage of erythema area,stratum corneum hydration,transepidermal water loss(TEWL),clinician′s erythema assessment(CEA),erythema and telangiectasia scores,dermatology life quality index(DLQI),and efficacy rate.Adverse reactions during treatment were also recorded.Results Compared with baseline,both groups exhibited significant reductions in percentage of erythema area,TEWL,CEA,erythema and telangiectasia score,and DLQI,and significant increases in stratum corneum hydration at each post-treatment time point(all P<0.05).After 2,4,6,and 8 weeks of treatment,the percentage of erythema area,erythema and telangiectasia scores in the study group were all lower than those in the control group,while the stratum corneum hydration level in the study group was higher than that in the control group(all P<0.05).After 4,6,and 8 weeks of treatment,TEWL,CEA,and DLQI in the study group were all lower than those in the control group(all P<0.05).After 4 weeks of treatment,the efficacy rate in the study group was 56.7%(17/30),which was higher than that of the control group at 23.3%(7/30,P=0.046).After 6 weeks of treatment,the efficacy rate in the study group was 83.3%(25/30),higher than that of the control group at 50.0%(15/30,P=0.020).After 8 weeks of treatment,the efficacy rate in the study group was 86.7%(26/30),higher than that of the control group at 66.7%(20/30,P<0.001).No severe adverse reactions were observed in either group.ConclusionTransdermal delivery of compound glycyrrhizin injection as an adjunctive treatment for ETR demonstrates favorable efficacy and good safety.
作者
黄纯钰
杜依林
冉卓昆
匡海霞
王钶韵
张鳌
杨颜玲
彭晓尹
林新瑜
Huang Chunyu;Du Yilin;Ran Zhuokun;Kuang Haixia;Wang Keyun;Zhang Ao;Yang Yanling;Peng Xiaoyin;Lin Xinyu(Department of Dermatology,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China;Department of Dermatology,Sichuan Provincial People′s Hospital,University of Electronic Science and Technology of China,Chengdu 610072,China;Department of Clinical Medicine,North Sichuan Medical College,Nanchong 637000,China)
出处
《中华医学美学美容杂志》
2025年第3期249-257,共9页
Chinese Journal of Medical Aesthetics and Cosmetology
基金
四川省卫计委科研项目(30504010774)。
关键词
玫瑰痤疮
中频药物导入治疗仪
经皮导入
复方甘草酸苷注射液
Rosacea
Medium-frequency drug-delivery therapeutic apparatus
Transdermal delivery
Compound glycyrrhizin injection
作者简介
通信作者:林新瑜,Email:linxinyu8989@163.com。
